{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:21:24Z","timestamp":1793395284388,"version":"4.5.0"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Colorectal cancer (CRC) is a deadly form of cancer worldwide. Patients with locally advanced rectal cancer and metastatic CRC have a poor long-term prognosis, and rational and effective treatment remains a major challenge. Common treatments include multi-modal combinations of surgery, radiotherapy, and chemotherapy; however, recurrence and metastasis rates remain high. The combination of radiotherapy and immunotherapy (radioimmunotherapy [RIT]) may offer new solutions to this problem, but its prospects remain uncertain. This review aimed to summarize the current applications of radiotherapy and immunotherapy, elaborate on the underlying mechanisms, and systematically review the preliminary results of RIT-related clinical trials for CRC. Studies have identified several key predictors of RIT efficacy. Summarily, rational RIT regimens can improve the outcomes of some patients with CRC, but current study designs have limitations. Further studies on RIT should focus on including larger sample sizes and optimizing the combination therapy regimen based on underlying influencing factors.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1105180","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T19:03:29Z","timestamp":1683745409000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":59,"title":["Radioimmunotherapy in colorectal cancer treatment: present and future"],"prefix":"10.3389","volume":"14","author":[{"given":"Jingyi","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoya","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haopeng","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal cancer: a review","volume":"325","author":"Biller","year":"2021","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"106663","DOI":"10.1016\/j.intimp.2020.106663","article-title":"Abscopal effect in radioimmunotherapy","volume":"85","author":"Ashrafizadeh","year":"2020","journal-title":"Int Immunopharmacol."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2034","article-title":"Radiotherapy and immunotherapy for cancer: from \u201cSystemic\u201d to \u201cMultisite\u201d","volume":"26","author":"Arina","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0051","article-title":"Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Benson","year":"2022","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"key":"B6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.radonc.2022.04.013","article-title":"Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer - the RAPIDO trial","volume":"171","author":"Dijkstra","year":"2022","journal-title":"Radiother Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000001987","article-title":"Acute adverse events and postoperative complications in a randomized trial of preoperative short-course radiotherapy versus long-course chemoradiotherapy for T3 adenocarcinoma of the rectum: trans-Tasman radiation oncology group trial (TROG 01.04)","author":"Ansari","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znab020","article-title":"Short-course radiotherapy with consolidation chemotherapy versus conventionally fractionated long-course chemoradiotherapy for locally advanced rectal cancer: randomized clinical trial","volume":"108","author":"Chakrabarti","year":"2021","journal-title":"Br J Surg"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000003471","article-title":"Total neoadjuvant therapy in rectal cancer: a systematic review and meta-analysis of treatment outcomes","volume":"271","author":"Petrelli","year":"2020","journal-title":"Ann Surg"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13824","article-title":"Total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis","volume":"26","author":"Liu","year":"2021","journal-title":"oncologist"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.36666","article-title":"Incidence and survival in synchronous and metachronous liver metastases from colorectal cancer","volume":"5","author":"Reboux","year":"2022","journal-title":"JAMA network Open"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.07.030","article-title":"Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer","volume":"99","author":"Joo","year":"2017","journal-title":"Int J Radiat oncology biology Phys"},{"key":"B13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13045-019-0702-0","article-title":"Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition)","volume":"12","author":"Li","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000005466","article-title":"Importance of local ablative therapies for lung metastases in patients with colorectal cancer","author":"Lee","year":"2022","journal-title":"Ann Surg"},{"key":"B15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-017-0453-8","article-title":"Immunotherapy in hematologic malignancies: past, present, and future","volume":"10","author":"Im","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3747\/co.25.3840","article-title":"Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges","volume":"25","author":"Nixon","year":"2018","journal-title":"Curr Oncol (Toronto Ont.)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01624","article-title":"Colorectal cancer immunotherapy: options and strategies","volume":"11","author":"Johdi","year":"2020","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","article-title":"Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways","volume":"19","author":"Kraehenbuehl","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.103","article-title":"Programmed death-1 blockade in mismatch repair deficient colorectal cancer","volume":"34","author":"Le","year":"2016","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"16-16","DOI":"10.1200\/JCO.2022.40.4_suppl.016","article-title":"PD-1 blockade alone for mismatch repair deficient (dMMR) locally advanced rectal cancer","volume":"40","author":"Lumish","year":"2022","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Sci (New York N.Y.)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s002590100570","article-title":"Radioimmunotherapy of b-cell non-hodgkin\u2019s lymphoma","volume":"28","author":"Postema","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0037","article-title":"Phase I study of p-cadherin-targeted radioimmunotherapy with 90Y-FF-21101 monoclonal antibody in solid tumors","volume":"26","author":"Subbiah","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(86)90071-4","article-title":"Distribution of radiation sensitivities for human tumor cells of specific histological types: comparison of in vitro to in vivo data","volume":"12","author":"Malaise","year":"1986","journal-title":"Int J Radiat oncology biology Phys"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/0300060519855595","article-title":"Radiotherapy activates autophagy to increase CD8+ T cell infiltration by modulating major histocompatibility complex class-I expression in non-small cell lung cancer","volume":"47","author":"Zeng","year":"2019","journal-title":"J Int Med Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2016.09.007","article-title":"Immune priming of the tumor microenvironment by radiation","volume":"2","author":"Jiang","year":"2016","journal-title":"Trends Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.005","article-title":"Emerging concepts for immune checkpoint blockade-based combination therapies","volume":"33","author":"Zappasodi","year":"2018","journal-title":"Cancer Cell"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1259\/0007-1285-26-305-234","article-title":"Whole body irradiation; radiobiology or medicine","volume":"26","author":"MOLE","year":"1953","journal-title":"Br J Radiol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.151","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Tanaka","year":"2017","journal-title":"Cell Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000826","article-title":"Combination of radiotherapy and suppression of tregs enhances abscopal antitumor effect and inhibits metastasis in rectal cancer","volume":"8","author":"Ji","year":"2020","journal-title":"J immunother Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ccell.2021.08.008","article-title":"Simultaneous targeting of TGF-\u03b2\/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion","volume":"39","author":"Lan","year":"2021","journal-title":"Cancer Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001610","article-title":"Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer","volume":"9","author":"Seo","year":"2021","journal-title":"J For Immunother Cancer."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1678","article-title":"Microsatellite instability as a biomarker for PD-1 blockade","volume":"22","author":"Dudley","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"New Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2019.06.004","article-title":"A pilot study of the PD-1 targeting agent AMP-224 used with low-dose cyclophosphamide and stereotactic body radiation therapy in patients with metastatic colorectal cancer","volume":"18","author":"Floudas","year":"2019","journal-title":"Clin colorectal Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4632","article-title":"A randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation for patients with metastatic colorectal cancer","volume":"27","author":"Monjazeb","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2474","article-title":"Phase II single-arm study of durvalumab and tremelimumab with concurrent radiotherapy in patients with mismatch repair-proficient metastatic colorectal cancer","volume":"27","author":"Segal","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00269-7","article-title":"Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial","volume":"2","author":"Parikh","year":"2021","journal-title":"Nat Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s13014-020-01673-6","article-title":"Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma","volume":"15","author":"Shamseddine","year":"2020","journal-title":"Radiat Oncol (London England)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.1683","article-title":"Use of total neoadjuvant therapy for locally advanced rectal cancer: initial results from the pembrolizumab arm of a phase 2 randomized clinical trial","volume":"7","author":"Rahma","year":"2021","journal-title":"JAMA Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"S223","DOI":"10.1016\/j.annonc.2021.05.016","article-title":"O-12 phase II study of preoperative chemoradiotherapy plus avelumab in patients with locally advanced rectal cancer: the AVANA study","volume":"32","author":"Salvatore","year":"2021","journal-title":"Ann Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003554","article-title":"Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer","volume":"9","author":"Lin","year":"2021","journal-title":"J immunother Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3213","article-title":"Preoperative chemoradiotherapy plus nivolumab before surgery in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer","volume":"28","author":"Bando","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"S537","DOI":"10.1016\/j.annonc.2021.08.919","article-title":"397P r-IMMUNE interim analysis: a phase Ib\/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with localized rectal cancer","volume":"32","author":"Carrasco","year":"2021","journal-title":"Ann Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-Instability-High advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"New Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01015","article-title":"First-line nivolumab plus low-dose ipilimumab for microsatellite instability-High\/Mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study","volume":"40","author":"Lenz","year":"2022","journal-title":"J Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejca.2016.06.015","article-title":"PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis","volume":"65","author":"Hecht","year":"2016","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.07.004","article-title":"Chemoradiation-induced alteration of programmed death-ligand 1 and CD8+ tumor-infiltrating lymphocytes identified patients with poor prognosis in rectal cancer: a matched comparison analysis","volume":"99","author":"Lim","year":"2017","journal-title":"Int J Radiat oncology biology Phys"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-019-02874-7","article-title":"Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy","volume":"145","author":"Chen","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejca.2017.12.005","article-title":"Pattern of programmed cell death-ligand 1 expression and CD8-positive T-cell infiltration before and after chemoradiotherapy in rectal cancer","volume":"91","author":"Ogura","year":"2018","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0071","article-title":"Adoption of total neoadjuvant therapy for locally advanced rectal cancer","volume":"4","author":"Cercek","year":"2018","journal-title":"JAMA Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13014-021-01888-1","article-title":"Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)","volume":"16","author":"Hanna","year":"2021","journal-title":"Radiat Oncol (London England)"},{"key":"B56","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12885-022-09348-z","article-title":"Short-course radiotherapy combined with CAPOX and toripalimab for the total neoadjuvant therapy of locally advanced rectal cancer: a randomized, prospective, multicentre, double-arm, phase II trial (TORCH)","volume":"22","author":"Wang","year":"2022","journal-title":"BMC Cancer"},{"key":"B57","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1186\/s12885-022-09554-9","article-title":"Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial)","volume":"22","author":"Yang","year":"2022","journal-title":"BMC Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4720","article-title":"Neoadjuvant treatment of sintilimab plus hypofractionated radiotherapy for MSI-H\/dMMR rectal cancer: a prospective, multicenter, phase ib study","volume":"11","author":"Li","year":"2022","journal-title":"Cancer Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1186\/s12885-022-09820-w","article-title":"Study protocol of a phase II study to evaluate safety and efficacy of neo-adjuvant pembrolizumab and radiotherapy in localized rectal cancer","volume":"22","author":"Corr\u00f2","year":"2022","journal-title":"BMC Cancer"},{"key":"B60","doi-asserted-by":"publisher","first-page":"TPS3623","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS3623","article-title":"Neoadjuvant chemoradiotherapy with sequential ipilimumab and nivolumab in rectal cancer (CHINOREC): a prospective randomized, open-label, multicenter, phase II clinical trial","volume":"39","author":"Laengle","year":"2021","journal-title":"J Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"New Engl J Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12943-016-0539-x","article-title":"Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer","volume":"15","author":"Li","year":"2016","journal-title":"Mol Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"New Engl J Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0337","article-title":"A diagnostic biopsy-adapted immunoscore predicts response to neoadjuvant treatment and selects patients with rectal cancer eligible for a watch-and-Wait strategy","volume":"26","author":"Sissy","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.19.00055","article-title":"Intratumoral CD3+ and CD8+ T-cell densities in patients with DNA mismatch repair-deficient metastatic colorectal cancer receiving programmed cell death-1 blockade","volume":"3","author":"Chakrabarti","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801199","article-title":"FGFR2 promotes expression of PD-L1 in colorectal cancer via the JAK\/STAT3 signaling pathway","volume":"202","author":"Li","year":"2019","journal-title":"J Immunol (Baltimore Md.: 1950)"},{"key":"B67","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1200\/JCO.18.00032","article-title":"Neoadjuvant (Chemo)radiotherapy with total mesorectal excision only is not sufficient to prevent lateral local recurrence in enlarged nodes: results of the multicenter lateral node study of patients with low cT3\/4 rectal cancer","volume":"37","author":"Ogura","year":"2019","journal-title":"J Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21731","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA: Cancer J Clin"},{"key":"B69","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1186\/s12885-018-4185-0","article-title":"The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: a systematic review","volume":"18","author":"Gebremedhn","year":"2018","journal-title":"BMC Cancer"},{"key":"B70","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s13046-021-02141-z","article-title":"Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development","volume":"40","author":"Yang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","first-page":"CD003455","DOI":"10.1002\/14651858.CD003455.pub2","article-title":"Non-surgical interventions for late rectal problems (proctopathy) of radiotherapy in people who have received radiotherapy to the pelvis","volume":"4","author":"van de Wetering","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B72","doi-asserted-by":"publisher","first-page":"102218","DOI":"10.1016\/j.ctrv.2021.102218","article-title":"Metastatic colorectal cancer: advances in the folate-fluoropyrimidine chemotherapy backbone","volume":"98","author":"Glimelius","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-017-5873-8","article-title":"Pathologic complete response rates after neoadjuvant treatment in rectal cancer: an analysis of the national cancer database","volume":"24","author":"Lorimer","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13046-021-01962-2","article-title":"Interferon- and STING-independent induction of type I interferon stimulated genes during fractionated irradiation","volume":"40","author":"Goedegebuure","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"B76","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA Exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1667\/RR14202.1","article-title":"Radiosensitization by PARP inhibition in DNA repair proficient and deficient tumor cells: proliferative recovery in senescent cells","volume":"185","author":"Alotaibi","year":"2016","journal-title":"Radiat Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4606","article-title":"Efficacy and toxic effects of cancer immunotherapy combinations-a double-edged sword","volume":"4","author":"Tang","year":"2018","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1105180\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T19:03:33Z","timestamp":1683745413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1105180\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":80,"alternative-id":["10.3389\/fimmu.2023.1105180"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1105180","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,10]]},"article-number":"1105180"}}